Project Grant R01CA307529
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $425K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $355,706 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2025, through May 31, 2030. The award funds fundamental research aimed at understanding the role of RAMS11 (RNA Associated with Metastasis 11), a long noncoding RNA (lncRNA), in non-small cell lung cancer (NSCLC) development and progression. The research addresses a critical knowledge gap in cancer biology...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant totaling $649,620 (awarded May 1, 2026; completion April 30, 2031) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on Medicare Advantage insurance impacts on cancer care access and outcomes. The research will analyze coverage patterns and care quality for beneficiaries with the four most prevalent cancers—breast, colorectal, lung,...
- Federal Grant Award Summary The National Cancer Institute awarded Kaiser Foundation Hospitals a $658,743 Project Grant (CFDA 93.393: Cancer Cause and Prevention Research) on August 25, 2025, to develop and validate predictive models for trajectories of physical function, cognition, and quality of life among adults aged 65 and older with advanced non-small cell lung cancer (NSCLC) undergoing systemic chemotherapy and/or immunotherapy. The five-year project, concluding July 31, 2030, builds on...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $542,644 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and preclinical evaluation of radiation-guided antibody-drug conjugates (ADCs) targeting Tax-Interacting Protein 1 (TIP1) as a novel therapeutic approach for non-small cell lung cancer (NSCLC). The research leverages a breakthrough...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University $101,771 under the Cancer Research Manpower program (CFDA 93.398) for a project grant beginning July 1, 2025, and concluding June 30, 2027. This award supports research investigating the impact of clonal hematopoiesis (CH)—specifically TET2 (Ten-Eleven Translocation 2) mutations in blood-forming cells—on solid tumor development and therapeutic response. The project will deliver fundamental...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $2.99 million Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 23, 2025, with completion targeted for August 31, 2029. The award funds a research initiative to characterize trends and outcomes of lung cancer screening (LCS) among people with HIV (PWH) in the United States, addressing a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), through its Cancer Research Manpower program (CFDA 93.398), awarded The Washington University a Project Grant of $333,504 effective July 1, 2025, through July 31, 2027. This award funds research investigating the dynamics and function of peritoneal myeloid cells during colorectal cancer (CRC) peritoneal dissemination and the implications for immunotherapy. The research aims to elucidate the unique roles of myeloid...
- Federal Grant Award Summary Massachusetts General Hospital (The General Hospital Corporation) received a $429,399 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period September 1, 2025 through August 31, 2027. The award supports the recalibration of the Lung Cancer Policy Model (LCPM) to address critical limitations in how the model estimates the effectiveness and cost-effectiveness of low-dose computed tomography...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.72 million Project Grant to Massachusetts General Hospital on June 1, 2025 (ultimate completion date April 30, 2030) under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and their family caregivers. The...
- Federal Grant Award Summary Washington University, through its Office of Sponsored Research Services, received a $1,594,797 Cooperative Agreement from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), awarded September 4, 2025, with completion targeted for August 31, 2027. The primary product is a rigorous implementation science evaluation designed to scale and sustain tobacco use treatment (TUT) in cancer survivors across...